ascopubs.org

Human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3) mutations to reveal biological pathways in urothelial carcinoma.

This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text component.
The Manila Times

Uni-Bio Science Joins Forces with WMU NERC and Ouhai District Government to Build Growth Factor Innovation Ecosystem and Accelerate Regenerative Medicine Strateg…

HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the ...
BMJ Case Reports

Relationship between recurrent colorectal cancer and EGFR inhibitor-induced dermatological side effects: a focus on paronychia

This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal ...
Business Insider

Dermatologists say people with sensitive skin should try EGFs, a less drying alternative to retinol

Epidermal growth factors (EGF) can fight wrinkles and dry skin similarly to retinol. Experts say EGFs can be an alternative to retinol for people with dry or sensitive skin. EGFs work by telling old ...